Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2 G2019S carriers and in vivo

7 Aug 2015

Abstract excerpt

OBJECTIVE: To further characterize mitochondrial dysfunction in LRRK2(G2019S) mutant Parkinson disease (PD) patient tissue (M-LRRK2(G2019S)), determine whether ursodeoxycholic acid (UDCA) also exerts a beneficial effect on mitochondrial dysfunction in nonmanifesting LRRK2(G2019S) mutation carriers (NM-LRRK2(G2019S)), and assess UDCA for its beneficial effect on neuronal dysfunction in vivo. METHODS: Intracellular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lysosomal Storage Disorders Research
Share to Neurological disorders and treatments
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26253449
DOI: 10.1212/wnl.0000000000001905

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2 G2019S carriers and in vivoPMID 26253449Read ↗

Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease.Semantic proximity Read ↗

Mitochondrial Phenotypes in Parkinson's Diseases-A Focus on Human iPSC-Derived Dopaminergic Neurons.Semantic proximity Read ↗

Mitochondrial Mechanisms of LRRK2 G2019S PenetranceSemantic proximity Read ↗

Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2.Semantic proximity Read ↗

Targeting Mitochondrial Impairment in Parkinson's Disease: Challenges and OpportunitiesSemantic proximity Read ↗

LRRK2-mediated mitochondrial dysfunction in Parkinson's disease.Semantic proximity Read ↗

Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson’s diseaseSemantic proximity Read ↗

LRRK2 and mitochondria: Recent advances and current views.Semantic proximity Read ↗

Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in miceSemantic proximity Read ↗

Mitochondrial Dysfunction in Genetic Animal Models of Parkinson's DiseaseSemantic proximity Read ↗

Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer's Disease.Semantic proximity Read ↗

Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.